Incyte Corporation INCY PDUFA priority review

When:
February 24, 2019 – February 25, 2019 all-day
2019-02-24T00:00:00-05:00
2019-02-26T00:00:00-05:00

Incyte Corporation $INCY has PDUFA priority review for Ruxolitinib Graft versus host disease on February 24, 2019.

See Press Release:

Results of REACH1 Study of Ruxolitinib (Jakafi®) for the Treatment of Acute Graft-Versus-Host Disease Demonstrate Rapid and Durable Patient Benefit

What is your Opinion?